Journal
BLOOD
Volume 119, Issue 10, Pages 2293-2301Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-08-374058
Keywords
-
Categories
Funding
- National Institutes of Health [5 P01-CA081534, R37-CA049870]
- European Society of Clinical Microbiology and Infectious Diseases
- Austrian Science Fund [J2750-B11]
- Austrian Society of Hematology and Oncology
- Initiative for Cancer Research of the Medical University of Vienna
Ask authors/readers for more resources
Leukemia cells from patients with chronic lymphocytic leukemia (CLL) express a highly restricted immunoglobulin heavy variable chain (IGHV) repertoire, suggesting that a limited set of antigens reacts with leukemic cells. Here, we evaluated the reactivity of a panel of different CLL recombinant antibodies (rAbs) encoded by the most commonly expressed IGHV genes with a panel of selected viral and bacterial pathogens. Six different CLL rAbs encoded by IGHV1-69 or IGHV3-21, but not a CLL rAb encoded by IGHV4-39 genes, reacted with a single protein of human cytomegalovirus (CMV). The CMV protein was identified as the large structural phosphoprotein pUL32. In contrast, none of the CLL rAbs bound to any other structure of CMV, adenovirus serotype 2, Salmonella enterica serovar Typhimurium, or of cells used for propagation of these microorganisms. Monoclonal anti-bodies or humanized rAbs of irrelevant specificity to pUL32 did not react with any of the proteins present in the different lysates. Still, rAbs encoded by a germ line IGHV1-69 51p1 allele from CMV-seropositive and -negative adults also reacted with pUL32. The observed reactivity of multiple different CLL rAbs and natural antibodies from CMV-seronegative adults with pUL32 is consistent with the properties of a super-antigen. (Blood. 2012;119(10):2293-2301)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available